Evidence map›Paper›PMID 41223812›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

Acid ceramidase as a novel target for adiponectin receptor agonist to abrogate podocyte NLRP3 inflammasome activation and glomerular inflammation during obesity.

Guangbi Li, Dandan Huang, Jason M Kidd, Yao Zou, Xiaoyuan Wu, Yang Zhang, Todd W B Gehr, Ningjun Li, Pin-Lan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guangbi LiDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
Dandan HuangDepartment of Biochemistry and Molecular Biology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
Jason M KiddDivision of Nephrology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
Yao ZouDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
Xiaoyuan WuDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
Yang ZhangDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas.
Todd W B GehrDivision of Nephrology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
Ningjun LiDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
Pin-Lan LiDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia. Electronic address: pin-lan.li@vcuhealth.org.

Funding

Hypertension and glomerular injury in hyperhomocysteinemia - role of inflammatory exosomesR01DK054927 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, PINLAN · 1998 to 2023
$6.7M
Lysosome dysfunction in podocytopathy and associated hypertensionR01DK120491 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, PINLAN · 2018 to 2022
$2.4M
NIDDK NIH HHS R01 DK054927NIDDK NIH HHS R01 DK120491
6 · The paper itself

Abstract

Adiponectin receptor (AdipoR) agonists protect against glomerular inflammation and injury in obesity-related glomerulopathy (ORG), but their molecular mechanisms remain unclear. Given the implication of the ceramide signaling pathway in the pathogenesis of ORG, the present study tested whether AdipoR agonists target acid ceramidase (AC) to inhibit NLRP3 inflammasome activation in podocytes, thereby blocking glomerular inflammation and injury during obesity. Confocal microscopy showed that adiponectin attenuated visfatin-induced NLRP3 inflammasome activation and IL-1β-containing multivesicular body (MVB) formation in podocytes. Nanoparticle tracking analysis revealed that adiponectin suppressed visfatin-induced extracellular vesicle release, an effect dependent on AC activity. Structured illumination microscopy demonstrated that visfatin reduced lysosome-MVB interaction in podocytes, which was restored by adiponectin via enhancement of TRPML1 channel-mediated Ca

Indexed as

Acid CeramidaseInflammasomesKidney GlomerulusNLR Family, Pyrin Domain-Containing 3 ProteinObesityPodocytesReceptors, AdiponectinAdiponectinAnimalsDiet, High-FatHumansInflammationMaleMiceMice, Inbred C57BLAcid CeramidaseAdiponectinInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseReceptors, AdiponectinAcid ceramidaseAdiponectin receptor agonistExtracellular vesicleNLRP3 inflammasomePodocyte

Identifiers

PMID41223812
PMCPMC13165501

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.